Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma

6 Aug 2020

Abstract excerpt

BACKGROUND: The sensitivity of myelocytomatosis oncogene (MYC) amplified medulloblastoma to class I histone deacetylase (HDAC) inhibition has been shown previously; however, understanding the underlying molecular mechanism is crucial for selection of effective HDAC inhibitors for clinical use. The aim of this study was to investigate the direct molecular interaction of MYC and class I HDAC2, and the impact of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Glioma Diagnosis and Treatment
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32822486
DOI: 10.1093/neuonc/noaa191

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastomaPMID 32822486Read ↗

Targeting class I histone deacetylases in cancer therapySemantic proximity Read ↗

Epigenetic Dysregulation in MYCN-Amplified NeuroblastomaSemantic proximity Read ↗

Characterization of an RNA binding protein interactome reveals the targetable post-transcriptional landscape of MYC-amplified medulloblastomaSemantic proximity Read ↗

c-Myc as a therapeutic target in cancerSemantic proximity Read ↗

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) MedulloblastomaSemantic proximity Read ↗

PRMT5 as an Epigenetic Target for Group 3 (MYC-driven) MedulloblastomaSemantic proximity Read ↗

Histone deacetylases as therapeutic targets in hematologic malignanciesSemantic proximity Read ↗

Global MYCN Transcription Factor Binding Analysis in Neuroblastoma Reveals Association with Distinct E-Box Motifs and Regions of DNA HypermethylationSemantic proximity Read ↗

Multi-Omics Analysis Identifies MGA as a Negative Regulator of the MYC Pathway in Lung Adenocarcinoma.Semantic proximity Read ↗

MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coinSemantic proximity Read ↗

c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in CancerSemantic proximity Read ↗

Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding InterfaceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.